Blood Markers to Gauge Heart Inflammation from Lung Cancer Immunotherapy
Studies blood markers in adults with lung cancer and drug-related heart inflammation.
Plain-language title generated from the registry record
Registry title: Biomarkers for Clinical Classification and Outcomes of Immune Checkpoint Inhibitor-Related-Related Myocarditis in Lung Cancer
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with lung cancer who developed heart muscle inflammation (myocarditis) after immune checkpoint inhibitor treatment. Blood markers will be studied.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Lung cancer confirmed by tissue examination, with immune checkpoint inhibitor-related myocarditis diagnosed by a doctor
- Earlier treatment
- Must have received at least one dose of immune checkpoint inhibitor therapy
Main reasons for not taking part
- Pregnant or breastfeeding
- Severe heart or blood vessel disease, or a recent acute heart event such as a heart attack or severe arrhythmia
- Another cancer, an immune-suppressing disease or an autoimmune disease at the same time
- Cannot complete the required tests and follow-up visits
Read by machine on 12 November 2026.
Where in China
- Shanghai Chest HospitalShanghai, ChinaContact: Yanbin Kuang, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Chest Hospital
- Trial code
- NCT06818149
- Record updated
- 10 February 2025
- Original description
This study aims to investigate the clinical classification and outcome-related biomarkers of immune checkpoint inhibitor (ICI)-related myocarditis in patients with lung cancer.A total of 50 patients with ICI-related myocarditis will be enrolled, including 25 with severe/critical myocarditis and 25 with subclinical/mild myocarditis. Blood samples will be collected at baseline and at follow-up time points (3 days, 7 days, and before discharge). Traditional myocardial injury markers, iron metabolism-related markers, and immunological markers will be measured and compared between groups. Changes in biomarkers after treatment will also be assessed. Clinical information such as in-hospital mortality and 3-month survival rates will be integrated to develop a severity assessment model. This model aims to evaluate disease severity and prognostic risk accurately by combining biomarkers, enhancing their application in clinical management.Read full original descriptionShow less
A Study on the Clinical Classification and Outcome-Related Biological Markers of Immune Checkpoint Inhibitor-Related Myocarditis in Lung Cancer Patients
This study aims to investigate the clinical classification and outcome-related biomarkers of immune checkpoint inhibitor (ICI)-related myocarditis in patients with lung cancer.A total of 50 patients with ICI-related myocarditis will be enrolled, including 25 with severe/critical myocarditis and 25 with subclinical/mild myocarditis. Blood samples will be collected at baseline and at follow-up time points (3 days, 7 days, and before discharge). Traditional myocardial injury markers, iron metabolism-related markers, and immunological markers will be measured and compared between groups. Changes in biomarkers after treatment will also be assessed. Clinical information such as in-hospital mortality and 3-month survival rates will be integrated to develop a severity assessment model. This model aims to evaluate disease severity and prognostic risk accurately by combining biomarkers, enhancing their application in clinical management.
Inclusion: Pathologically confirmed lung cancer and having received at least one dose of immune checkpoint inhibitor therapy; Clinically diagnosed with immune checkpoint inhibitor-related myocarditis; Aged 18 years or older; Voluntarily signed informed consent after being fully informed.
Exclusion: Concurrent other malignancies, immunosuppressive diseases, or autoimmune diseases; Presence of severe underlying cardiovascular diseases or recent acute cardiac events (e.g., myocardial infarction, severe arrhythmia); Pregnancy or breastfeeding; Inability to complete the required examinations and follow-ups specified in the study.